TD Cowen analyst Phil Nadeau has maintained their bullish stance on KURA stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Phil Nadeau has given his Buy rating due to a combination of factors that highlight Kura Oncology’s promising position in the market. The company is poised for the approval of ziftomenib for relapsed/refractory NPM1 AML by the end of November, which is expected to be a significant milestone. The management has expressed confidence in their commercial readiness for the launch and has been actively engaging with the FDA, suggesting a smooth path to approval.
Additionally, the pivotal data from the KOMET-017 program in first-line AML and the promising results from the Phase 1b study of ziftomenib in combination with venetoclax and azacitidine show strong efficacy and safety profiles. The market research indicates a favorable risk-benefit perception among key opinion leaders and community physicians. These factors, combined with the high unmet need in the AML space, suggest that ziftomenib could capture a substantial market share, supporting the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $40.00 price target.